PepGen Inc.
HealthcareNASDAQ:PEPG · NASDAQ Global Select
-$0.04 today
Vol 0.22M · Avg 1.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-60.8%
avg -46.0%
ROIC
-56.9%
avg -43.1%
ROA
-51.6%
avg -38.1%
Analysis
ROA is currently the strongest return metric at -51.6% versus its period average of -38.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James G. McArthur | President, Chief Executive Officer, Treasurer, Secretary & Director | $1.06M | — | 64 | $296,326.00 | 0.43% |
Noel Donnelly | Chief Financial Officer | $742,595.00 | — | 56 | $111,655.00 | 0.16% |
Joseph D. Vittiglio | Chief Business & Legal Officer and Secretary | $391,638.00 | — | 54 | $120,000.00 | 0.17% |
Paul D. Streck | Executive Vice President and Head of Research & Development | $332,733.00 | — | 62 | $76,226.00 | 0.11% |
Hayley Parker | Senior Vice President of Global Regulatory Affairs & Quality | — | — | — | — | — |
Gregory Song | Executive Director & Head of Biometrics | — | — | — | — | — |
Emiko Bryant | Senior Vice President of HR & Administration | — | — | — | — | — |
Melissa Michaels | Executive Director & Head of Regulatory Affairs CMC | — | — | — | — | — |
Pallavi Lonkar | Vice President & Head of Preclinical | — | — | — | — | — |
Kasra Kasraian | Chief Technology Officer | — | — | 59 | $50,074.00 | 0.07% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$30.64M
Sells
7
$59,312.24
Net Sentiment
+$30.58M
Net buying
Most Active
McArthur James G
2 transactions
Analysis
Insiders reported 2 buys worth $30.64M and 7 sells worth $59,312.24 over the last 12 months. That adds up to net buying of $30.58M. McArthur James G was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Fate Therapeutics, Inc.
NASDAQ:FATE
$240.11M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
Cassava Sciences, Inc.
SAVA
$63.77M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages PEPG?
PepGen Inc. (PEPG) lists 10 active executives. The top listed executive is Joseph D. Vittiglio, Chief Business & Legal Officer and Secretary.
Are PEPG insiders buying or selling?
Recent insider activity shows net buying of $140.08M.
Explore More
Continue the stock analysis
Jump to another research area for this company.